I have a question; what exactly is the asset here now? Almost a certainty iih is done. They will pay a cool million for a team of consultants to say is not viable (why even raise the prospect of a review if they aren't almost certain of the answer. Otherwise they are just weakening the commercially of the asset). Perhaps TBI. Perhaps care and maintenance and wages until biotech is in vogue again, then pump something for the pros to exit on....
